ProMIS Neurosciences (PMN) officer buys 6,595 shares and matching warrants

Rhea-AI Filing Summary

ProMIS Neurosciences principal accounting officer Max A. Milbury reported purchasing additional equity in the company. On February 3, 2026, he acquired 6,595 common shares of ProMIS Neurosciences Inc. at a purchase price of $12.13 per share under a Securities Purchase Agreement with selected investors.

He also received common share purchase warrants to buy 6,595 additional common shares. These warrants are exercisable starting February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from cohorts treated with single ascending doses of PMN310. Following the transaction, he beneficially owned 8,409 common shares and 6,595 warrants, all held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Milbury Max A.

Role Insider

Type	Security	Shares	Price	Value
Grant/Award	Warrants to purchase Common Shares	6,595	$0.00	--
Grant/Award	Common Shares	6,595	$12.13	$80K

Holdings After Transaction: Warrants to purchase Common Shares — 6,595 shares (Direct); Common Shares — 8,409 shares (Direct)

Footnotes (1)

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milbury Max A.

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

1920 YONGE STREET, SUITE 200

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		A(1)		6,595	A	$12.13(1)	8,409(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase Common Shares	$14.4	02/03/2026		A(1)		6,595		02/03/2026	02/03/2031(3)	Common Shares	6,595	(1)	6,595	D

Explanation of Responses:

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,595 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,595 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

2. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

3. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

	/s/ Max A. Milbury	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report for Max A. Milbury?

ProMIS Neurosciences reported that Principal Accounting Officer Max A. Milbury acquired 6,595 common shares on February 3, 2026. He also received warrants to purchase an additional 6,595 common shares under a Securities Purchase Agreement with selected investors at a stated purchase price of $12.13.

At what price did Max A. Milbury buy ProMIS Neurosciences (PMN) shares and warrants?

Max A. Milbury acquired 6,595 common shares and accompanying common share purchase warrants at a purchase price of $12.13 per common share and warrant. The transaction was executed on February 3, 2026 pursuant to a Securities Purchase Agreement with selected investors.

How many ProMIS Neurosciences (PMN) shares does Max A. Milbury own after this Form 4?

After the reported transaction, Max A. Milbury beneficially owned 8,409 common shares of ProMIS Neurosciences Inc. He also directly held common share purchase warrants exercisable for an additional 6,595 common shares, increasing his potential equity exposure if the warrants are exercised.

What warrants did Max A. Milbury receive from ProMIS Neurosciences (PMN)?

He received common share purchase warrants to buy 6,595 common shares. The warrants are exercisable from February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced or reported on Form 8-K.

How does the PMN310 trial data affect Max A. Milbury’s ProMIS warrants?

The common share purchase warrants held by Max A. Milbury will expire earlier if topline data from cohorts treated with single ascending doses of PMN310 are publicly announced. Expiry occurs within 60 days of that announcement or related Form 8-K filing, if that comes before February 3, 2031.

What corporate role does Max A. Milbury hold at ProMIS Neurosciences (PMN)?

Max A. Milbury is identified as the Principal Accounting Officer of ProMIS Neurosciences Inc. in the filing. The Form 4 indicates that the reported common shares and common share purchase warrants are held directly by him rather than through an intermediate entity or trust.